173 related articles for article (PubMed ID: 33792689)
21. Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
Cessario J; Pierre-Louis V; Wahl J; Li Z
Pharmacol Rep; 2021 Jun; 73(3):858-867. PubMed ID: 33555600
[TBL] [Abstract][Full Text] [Related]
22. Anti-inflammatory potential of Empagliflozin.
Pirklbauer M
Inflammopharmacology; 2021 Apr; 29(2):573-576. PubMed ID: 33728540
[No Abstract] [Full Text] [Related]
23. Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor.
Jhuo SJ; Liu IH; Tsai WC; Chou TW; Lin YH; Wu BN; Lee KT; Lai WT
Molecules; 2020 Aug; 25(16):. PubMed ID: 32784369
[TBL] [Abstract][Full Text] [Related]
24. The cardioprotective potential of the sodium-glucose cotransporter 2 inhibitor empagliflozin in donor heart preservation.
Villanueva JE; Gao L; Doyle A; Scheuer SE; Hicks M; Jabbour A; Macdonald PS
J Heart Lung Transplant; 2020 Oct; 39(10):1151-1153. PubMed ID: 32650984
[No Abstract] [Full Text] [Related]
25. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na
Uthman L; Li X; Baartscheer A; Schumacher CA; Baumgart P; Hermanides J; Preckel B; Hollmann MW; Coronel R; Zuurbier CJ; Weber NC
Biomed Pharmacother; 2022 Feb; 146():112515. PubMed ID: 34896968
[TBL] [Abstract][Full Text] [Related]
26. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
27. Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Cherney DZI; Bjornstad P; Perkins BA; Rosenstock J; Neubacher D; Marquard J; Soleymanlou N
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1715-1719. PubMed ID: 34535454
[No Abstract] [Full Text] [Related]
28. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
29. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
[TBL] [Abstract][Full Text] [Related]
30. Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.
Lee TI; Chen YC; Lin YK; Chung CC; Lu YY; Kao YH; Chen YJ
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987285
[TBL] [Abstract][Full Text] [Related]
31. Empagliflozin decreases myocardial cytoplasmic Na
Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
[TBL] [Abstract][Full Text] [Related]
32. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
Lahnwong C; Palee S; Apaijai N; Sriwichaiin S; Kerdphoo S; Jaiwongkam T; Chattipakorn SC; Chattipakorn N
Cardiovasc Diabetol; 2020 Jun; 19(1):91. PubMed ID: 32539724
[TBL] [Abstract][Full Text] [Related]
33. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
[TBL] [Abstract][Full Text] [Related]
34. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
35. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
[TBL] [Abstract][Full Text] [Related]
36. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
[TBL] [Abstract][Full Text] [Related]
37. Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a.
Goerg J; Sommerfeld M; Greiner B; Lauer D; Seckin Y; Kulikov A; Ivkin D; Kintscher U; Okovityi S; Kaschina E
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063987
[TBL] [Abstract][Full Text] [Related]
38. Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K
Seo MS; Jung HS; An JR; Kang M; Heo R; Li H; Han ET; Yang SR; Cho EH; Bae YM; Park WS
Toxicol Appl Pharmacol; 2020 Sep; 403():115153. PubMed ID: 32717242
[TBL] [Abstract][Full Text] [Related]
39. Empagliflozin Attenuates Arrhythmias in an iPSC-Based Model of Hypertrophic Cardiomyopathy.
Arthur Ataam J; Belbachir N; Perea-Gil I; Termglinchan V; Vadgama N; Garg P; Ramchandani R; Gavidia AA; Roura S; Gálvez-Montón C; Wu JC; Bayés-Genis A; Karakikes I
Circ Genom Precis Med; 2024 Jun; 17(3):e004526. PubMed ID: 38752368
[No Abstract] [Full Text] [Related]
40. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
Olgar Y; Turan B
Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
